Genome Analysis Across Populations in Inflammatory Bowel Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMount Sinai Hospital, Canada
About this trial
Objective:
To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Eligibility criteria
Qualifiers
Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
Any age
Disqualifiers
None
Trial design
Treatments tested in this trial
- Blood or saliva sample collection
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Mount Sinai Hospital, Canada
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov